Generic dolutegravir-based FDCs at US $75 a year for low- and middle-income countries
1 December 2017. Related: Treatment access.
Polly Clayden, HIV i-Base
A new pricing agreement has been announced that will speed up access to generic, dolutegravir-based fixed dose combinations (FDCs).
This will enable use to treat HIV in low- and middle-income countries (LMICs) at an annual cost per person of around US $75.